Chandan Das

Dr. Chandan Das

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 March 2021 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Closed access
PDF file
SSSwayamjeet Satapathy
Swayamjeet Satapathy
ASAshwani Sood
Ashwani Sood
CDChandan Das
Chandan Das
BMBhagwant Rai Mittal
Bhagwant Rai Mittal

1 November 2020 in JCO Global Oncology
Verified
Journal Article
Open access
APAmol Patel
Amol Patel
ITIan F. Tannock
Ian F. Tannock
PSPriyanka Srivastava
Priyanka Srivastava
BBBivas Biswas
Bivas Biswas
VGVineet Govinda Gupta
Vineet Govinda Gupta
PMPrashant Mehta
Prashant Mehta
PURPOSE: It is projected that approximately 50,000 new cases of prostate cancer will be diagnosed in 2020 in India. Survival has improved because of the development of effective drugs such as abiraterone acetate, but universal accessibility to treatment is not always possible because of cost constraints in lower- and middle-income countries. Recently, the National Comprehensive Cancer Network (NCCN) has included low-dose abiraterone (250 mg/day) with food as an alternative treatment option to full-dose abiraterone (1,000 mg/day) fasting.METHODS: The Science and Cost Cancer Consortium conducted a survey to evaluate the use of abiraterone in India and the opinions of medical oncologists about using low-dose treatment. Modeling was used to estimate potential financial benefits to individual patients and to estimate overall costs of health care in India if low-dose abiraterone is prescribed.RESULTS: Of 251 Indian medical oncologists who were invited to participate in the survey, 125 provided their e-mail address and received the survey; 118 responded (47% of the total). Of these, 25% were not aware of the recent NCCN recommendation, 55% were already prescribing low-dose abiraterone when resources were limited, 7% had already changed their practice, and 29% agreed to switch to a universal practice of using low-dose abiraterone with food; 9% of practitioners would not use low-dose abiraterone. Estimated mean per patient savings was US$3,640, with annual savings of US$182 million in India.CONCLUSION: Use of lower-dose abiraterone would increase access to treatment in India and globally and lead to large cost savings.

1 June 2020 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
RVRakhee Vatsa
Rakhee Vatsa
ASAshwani Dnb Sood
Ashwani Dnb Sood
SVShelvin Kumar Vadi
Shelvin Kumar Vadi
CDChandan Das
Chandan Das
KKKomalpreet Msc Kaur
Komalpreet Msc Kaur
BMBhagwant Rai Md Mittal
Bhagwant Rai Md Mittal
PSMA-based radioligand therapies have shown the beneficial effect in metastatic castrate-resistant prostate cancer (mCRPC) patients when they become refectory to the established treatments with associated potential toxicities and high mortality rate. 225Ac-PSMA therapy is known to be remarkably effective in substantially pretreated mCRPC patients. However, posttherapy imaging is usually not performed as alpha emitters are really difficult to image. We presents a patient of mCRPC treated with 225Ac-PSMA-617, and his posttherapy whole-body scans acquired by using 3 different photopeaks (78, 218, and 440 keV) fairly demonstrated the tracer's distribution and the efficacy of targeted alpha therapy.

1 July 2018 in South Asian Journal of Cancer
Verified
Journal Article
Open access
PDF file
AGAjay Gogia
Ajay Gogia
CDChandan Das
Chandan Das
LKLalit Kumar
Lalit Kumar
ASAtul Sharma
Atul Sharma
ATAkash Tiwari
Akash Tiwari
SMSoumya Mallick
Soumya Mallick
Introduction: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma. We conducted a retrospective study to analyze the clinicopathological characteristics, cell of origin, response to therapy, and the outcome of patients with DLBCL. Materials and Methods: This was a retrospective study which included all patients with DLBCL registered at our center, between May 1, 2013, and July 31, 2015. The data regarding demography, clinical presentation, histopathology, stage, prognostic index, treatment, and treatment-related outcome were collected from prospectively maintained clinical case records of the patients. Results: In the study, we included 267 patients. The median age is 49 (20–81) years with male: female ratio of 2:1. B symptoms were seen in 124 (45%) of patients. Early Stages (I and II) were seen in 130 (52%) patients, while advanced Stages (III and 1V) were seen in 119 (48%) patients. Bulky disease (>7.5 cm) was seen in 30% of cases, and bone marrow was involved in 12%. Extranodal involvement is present in 35% of cases. Cell of origin data was available in 160 (60%) of cases, of which 88 (55%) were germinal center and 72 (45%) were activated B cell in origin. The distribution according to the international prognostic index (IPI) was as follows: low risk 40%, intermediate risk 45%, and high risk in 15%. Rituximab was used in 45% of cases. The overall response rate was 84% with a complete response (CR) rate of 70.5%. The CR rates were better with RCHOP compared with CHOP (77% vs. 61.5%, P = 0.001) and good-risk IPI (83.3% vs. 65.2%, P < 0.001) compared with intermediate- and high-risk IPI. Median follow-up period was 24 months, and 2-year event-free survival (EFS) was 70%. The presence of B symptoms, high IPI, failure to attain CR, poor PS, and nonrituximab-based chemotherapy were significantly associated with lower EFS. Conclusions: This is the first study from India, which investigated the impact of chemotherapy with or without rituximab in context of cell of origin. Adding rituximab to CHOP showed better response rate and EFS irrespective of cell of origin.

1 December 2019 in Journal of Global Oncology
Verified
Journal Article
Open access
ABAtul Batra
Atul Batra
APAmol Patel
Amol Patel
VGVineet Govinda Gupta
Vineet Govinda Gupta
PMPrashant Mehta
Prashant Mehta
TTTilak Tvsvgk
Tilak Tvsvgk
PSPriyanka Srivastava
Priyanka Srivastava

19 October 2022 in The Prostate
Verified
Journal Article
Closed access
SSSwayamjeet Satapathy
Swayamjeet Satapathy
CDChandan Das
Chandan Das
PAPiyush Aggarwal
Piyush Aggarwal
ASAshwani Sood
Ashwani Sood
APAshwin S. Parihar
Ashwin S. Parihar
BMBhagwant R. Mittal
Bhagwant R. Mittal